XML 86 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combination and Asset Acquisitions Narrative (Details) (USD $)
3 Months Ended 9 Months Ended 0 Months Ended 9 Months Ended 0 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 0 Months Ended 3 Months Ended 9 Months Ended 0 Months Ended 0 Months Ended 7 Months Ended 0 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Jan. 13, 2014
Aerial [Member]
Upfront Payment [Member]
Sep. 30, 2014
Aerial [Member]
Milestone Payment [Member]
Sep. 30, 2014
Noncontrolling Interest [Member]
Jan. 23, 2014
Gentium [Member]
Feb. 20, 2014
Gentium [Member]
Sep. 30, 2014
Gentium [Member]
Aug. 31, 2014
Gentium [Member]
Sep. 30, 2013
Gentium [Member]
Sep. 30, 2014
Gentium [Member]
Sep. 30, 2013
Gentium [Member]
Jan. 23, 2014
Gentium [Member]
Dec. 19, 2013
Gentium [Member]
Jan. 23, 2014
Gentium [Member]
Product [Member]
Jan. 23, 2014
Gentium [Member]
Manufacturing Contracts [Member]
Sep. 30, 2014
Gentium [Member]
Selling, general and administrative [Member]
Sep. 30, 2014
Gentium [Member]
Selling, general and administrative [Member]
Feb. 20, 2014
Gentium [Member]
Ordinary Options and American Depositary Shares [Member]
Jan. 23, 2014
Gentium [Member]
Ordinary Options and American Depositary Shares [Member]
Feb. 20, 2014
Gentium [Member]
Ordinary Options and American Depositary Shares [Member]
Jan. 23, 2014
Gentium [Member]
Ordinary Options and American Depositary Shares [Member]
Jan. 23, 2014
Gentium [Member]
Noncontrolling Interest [Member]
Aug. 31, 2014
Gentium [Member]
Noncontrolling Interest [Member]
Jan. 23, 2014
Tender Offer Agreement [Member]
American Depositary Shares [Member]
Jan. 23, 2014
Tender Offer Agreement [Member]
Ordinary Options [Member]
Jul. 01, 2014
Sigma Tau [Member]
Aug. 04, 2014
Sigma Tau [Member]
Upfront Payment [Member]
Business Acquisition [Line Items]                                                            
Share price of cash tender offer (in dollars per share)                               $ 57.00                            
Shares tendered                                           12,244,156                
Issued and outstanding shares acquired, percentage                                               79.00%            
Fully diluted shares acquired, percentage                                           69.00%                
Total ownership interest acquired, percentage                                             98.00%              
Additional ownership interest acquired, percentage                     1.80%                   12.00%                  
Acquisition cost of noncontrolling interest     $ 136,950,000 $ 0             $ 17,800,000                             $ 137,000,000        
Net acquisition consideration                         994,000,000                                  
Total acquisition consideration, including subsequent acquisition                         1,011,100,000                                  
Proceeds from exercise of acquired share options                 17,100,000                                          
Total acquisition consideration               857,086,000                                            
Shares committed to tender offering                                                     1,345,023      
Options subject to support agreements                                                       1,666,608    
Ownership percentage                                           86.00%                
Transaction costs                         10,000,000                                  
Change in control obligation expenses                                     300,000 4,700,000                    
Revenue 306,584,000 232,160,000 844,733,000 636,649,000           21,100,000     57,100,000                                  
Net income (loss) 25,768,000 75,409,000 (24,285,000) 161,019,000     (1,060,000)                                              
Acquisition cost of a noncontrolling interest                                         119,200,000                  
Estimated fair value of trade receivables acquired                             13,900,000                              
Gross contractual amount of trade receivables acquired                             14,900,000                              
Estimated uncollectible amount of trade accounts receivables acquired                             1,000,000                              
Estimated remaining life                                 16 years 4 years                        
Issued and outstanding shares held by noncontrolling interests                                                 2,007,452          
Options not subject to support agreements held by noncontrolling interests                                                 484,097          
Pro forma adjustment, amortization expense                       12,200,000 2,800,000 36,700,000                                
Pro forma adjustment, transaction-related expense                         40,700,000                                  
Pro forma adjustment, interest expense                       5,700,000 1,400,000 16,900,000                                
Pro forma adjustment, non-recurring expenses                   (400,000)   500,000 (39,900,000) 17,800,000                                
Acquired in-process research and development 75,000,000 988,000 202,000,000 4,988,000 125,000,000 2,000,000                                               75,000,000
Potential milestone payments under agreement                                                         25,000,000  
Potential milestone payments for FDA approval of defibrotide (up to $150.0 million)                                                         150,000,000  
Maximum potential milestones payments           $ 270,000,000